Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 12/20 | 0.39 |
| ▸ | AXL | P30530 | 9/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313657 | 0.81 | POLB (0.46) | POLBHPGD | |
| SCHEMBL3143880 | 0.81 | KCNA5 (0.46) | PTGESPTGS2KCNA5MERTKAXL | |
| SCHEMBL3149527 | 0.78 | HPGD (0.57) | POLBHPGDKDM4EALDH1A1MAPT | |
| SCHEMBL3144414 | 0.77 | PTGES (0.46) | PTGESPTGS2KCNA5MERTKAXL | |
| SCHEMBL3149073 | 0.75 | KDM1A (0.50) | POLBHPGD | |
| SCHEMBL27701237 | 0.74 | KCNA5 (0.53) | PTGESPTGS2KCNA5MERTKAXL | |
| SCHEMBL4380010 | 0.74 | KMT2A (0.51) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL1928743 | 0.74 | KMT2A (0.51) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL14583914 | 0.74 | KMT2A (0.51) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL8280167 | 0.74 | KMT2A (0.51) | KCNA5MERTKAXLMETTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD3B1 | PTGES 491/4885PTGS2 345/4885KCNA5 994/4885 |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD3B1 | PTGES 491/4885PTGS2 345/4885KCNA5 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.